Navigation Links
Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer
Date:12/6/2007

SOUTH SAN FRANCISCO, Calif., Dec. 6 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that its corporate partner, Pfizer (NYSE: PFE), has begun a Phase 1 clinical trial of an inhaled formulation of Rigel's small molecule syk kinase inhibitor, R343, for the treatment of allergic asthma. R343 is the third product candidate in Rigel's clinical portfolio.

Under the terms of the companies' 2005 collaboration agreement, Rigel will receive a $5 million milestone payment from Pfizer for the commencement of this study. Pfizer retains exclusive rights to R343 and is responsible for its clinical development.

"Developing an inhaled drug product that may address an important pathway in the allergic response causing asthmatic airway obstruction and tissue damage gives new hope to millions of asthma sufferers," stated Donald G. Payan, M.D., executive vice president and chief scientific officer of Rigel. "We are proud to have Pfizer lead the development of R343."

Syk Kinase Inhibition in Allergic Asthma

Allergic asthma is a chronic inflammatory disorder of the airways resulting in airway obstruction. In some patients, allergens, such as pollen, trigger the production of immunoglobulin E (IgE) antibodies, which then bind to mast cells and transmit intracellular signals causing the allergic response. In May 2006, Pfizer selected R343 for advanced preclinical development aimed at inhibiting IgE receptor signaling in respiratory tract
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... CHENGDU, China , July 30, 2015 ... "Company"), a pharmaceutical company that specializes in the patented ... active pharmaceutical ingredients (API), provided updates regarding the notice ... MKT LLC (the "Exchange") indicating that the Company was ... set forth in Sections 134 and 1101 of the ...
(Date:7/30/2015)... , July 30, 2015 Eisai Inc. announced ... the United States , European Union and ... and MHLW, respectively) for eribulin, for the treatment of ... received prior chemotherapy for advanced or metastatic disease. ... from a pivotal global Phase 3 clinical trial (Study ...
(Date:7/30/2015)... , July 30, 2015 ... latest report titled, "Continuous Glucose Monitoring Systems Market: Global ... to the report, the global continuous glucose monitoring systems ... and is expected to reach US$ 788.4 Mn by ... period, 2015 to 2020. Global continuous glucose ...
Breaking Medicine Technology:TPI Provides Update Regarding Non-Compliance with NYSE MKT Continued Listing Requirements 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 2Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 3Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 4
... Reports Significantly More Patients Treated,with Taxotere(R)-Based ... CHICAGO, June 04, 2007 /PRNewswire-FirstCall/ -- ... maintained long-term efficacy as a treatment ... to the three-year updated results of ...
... - Schering-Plough Corp. announced results,from a Phase ... (pegylated liposomal doxorubicin hydrochloride),significantly prolonged time to ... with infrequent and manageable clinical,toxicity after first-line ... 43rd Annual Meeting of the American Society ...
Cached Medicine Technology:Updated Study Results Reinforce Survival Benefit of Taxotere,(Docetaxel) for Men with Advanced, Hormone-Resistant Prostate,Cancer 2Updated Study Results Reinforce Survival Benefit of Taxotere,(Docetaxel) for Men with Advanced, Hormone-Resistant Prostate,Cancer 3Updated Study Results Reinforce Survival Benefit of Taxotere,(Docetaxel) for Men with Advanced, Hormone-Resistant Prostate,Cancer 4Caelyx Delays Time to Disease Progression as Maintenance Therapy in,Patients with Metastatic Breast Cancer 2Caelyx Delays Time to Disease Progression as Maintenance Therapy in,Patients with Metastatic Breast Cancer 3Caelyx Delays Time to Disease Progression as Maintenance Therapy in,Patients with Metastatic Breast Cancer 4Caelyx Delays Time to Disease Progression as Maintenance Therapy in,Patients with Metastatic Breast Cancer 5
(Date:7/31/2015)... CA (PRWEB) , ... July 31, 2015 , ... ... by High Times magazine. What are the STASH awards? The Significant Technological ... made by the cannabis-cultivation community as well as tried-and-true products that have stood ...
(Date:7/31/2015)... ... August 01, 2015 , ... The Honor Society of Nursing, ... on the Future of Nursing (GAPFON) 20-21 July 2015 in San Juan, Puerto Rico. ... this meeting. , Dr. Silvia Cassiani, Advisor, Nursing and Allied Health Personnel Development, Unit ...
(Date:7/31/2015)... ... July 31, 2015 , ... Precision Aesthetics is New York’s only Thermage ... also the first provider of Exilis non-surgical fat reduction in New York. Due ... attracted a large International clientele. Many patients travel to New York to get ...
(Date:7/31/2015)... ... 2015 , ... The 2nd annual Ride to Fight On will start and ... 2015. The Ride to Fight On is a cycling fundraiser that benefits the West ... Clinic and The University of Tennessee Health Science Center. A health and wellness festival ...
(Date:7/31/2015)... ... July 31, 2015 , ... Jacksonville-based drug ... new True North Conference Center. The medical community, social workers, law enforcement, and ... be more aligned in the effort to better understand and combat sex trafficking. ...
Breaking Medicine News(10 mins):Health News:The High Times S.T.A.S.H. Awards Are in, Guess Who Took Home the Prize for “Best Grow System” 2Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 2Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 3Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 4Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 3Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 2Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 3
... ... global leader in strategic consulting, was named a 2009 “Purveyor of the Year” by ... has provided Outback Steakhouse with custom, strategic learning solutions to help cascade strategies throughout ... ...
... Innovative ... around the globe. , ... (PRWEB) April 9, 2010 -- CareCloud today announced that it has been selected ... innovative solutions are “disrupting the established enterprise and pioneering cloud computing and SaaS.” The ...
... Gastrointestinal (GI) chronic perforations require closure and control ... stents or plastic stents are an effective ... have many drawbacks. Using the newly designed ... bleeding to close two chronic inveterate external gastric ...
... Women should get retested whenever they change sexual partners, ... -- Once-a-year screening for chlamydia isn,t likely to protect ... A new study has found that most cases of ... chlamydia infection when they were screened, which suggests they ...
... ... emergency medical cache of disposable medical supplies, ready for quick use by patients and ... (PRWEB) ... of preparing for the possibility of a large scale health emergencies. Healthcare organizations need ...
... ... with the apps Rx for a busy life. ,Life gets hectic. Heck, ... mobile applications for iPhone, iPod touch, and the new IPad is on ... your busy life less stressful, less complicated and yes… more productive! Rooted ...
Cached Medicine News:Health News:Root Learning Named “Purveyor of the Year” For Strategic Partnership with Outback Steakhouse 2Health News:CareCloud Ranked Among Top SaaS Companies 2Health News:Yearly Chlamydia Screening May Be Ineffective for Some 2Health News:Provide Medical Surge Care with MasCache by DQE 2Health News:Dr. Appz Launches Comprehensive Productivity App for iPhone 2
Conforms to the convexity of the lens providing easier access to anterior capsule. Reduces pontential of corneal touch. 23G x 5/8in (.60 x 16mm)...
... LASIK surgery and other types of ... corneal interface and/or stromal bed. Flattened ... flap and helps elevate the flap ... x 7/8in (.40 x 22mm) Formed ...
... Unique product designed for LASIK ... surgery. Designed to irrigate the corneal ... provides easy insertion under the flap ... Multiple ports provide multi-directional irrigation. Two ...
... for LASIK surgery and other types of ... interface and/or stromal bed. Flattened tip provides ... elevate the flap edge. Multiple ports provide ... 22mm) Formed 7mm from end. Two .15mm ...
Medicine Products: